Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/microorganisms8081097 http://scihub22266oqcxt.onion/10.3390/microorganisms8081097 32707942!7463960!32707942     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32707942.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Microorganisms 2020 ; 8 (8): ä Nephropedia Template TP {{tp|p=32707942|t=2020. Evaluation of Current Therapies for COVID-19 Treatment |pdf=|usr=}}{{32707942}} gab.com Text Evaluation of Current Therapies for COVID-19 Treatment JO: Microorganisms http://www.kidney.de/pget.php?&tw=1&pmid=32707942 #FOAvip The virus SARS-CoV-2, the etiological agent of COVID-19, is responsible for more than 400,000 deaths worldwide as of 10 June 2020. As a result of its recent appearance (December 2019), an efficacious treatment is not yet available. Although considered a lung infection since its emergence, COVID-19 is now causing multiple organ failure, requiring a continuous adjustment in the procedures. In this review, we summarize the current literature surrounding unproven therapies for COVID-19. Analyses of the clinical trials were grouped as chemotherapy, serotherapy, anticoagulant, and the use of human recombinant soluble ACE2 therapies. We conclude that, while no agent has hit the threshold for quality of evidence to demonstrate efficacy and safety, preliminary data show potential benefits. Moreover, there is a possibility for harm with these unproven therapies, and the decision to treat should be based on a comprehensive risk-benefit analysis. Twit Text FOAVip Evaluation of Current Therapies for COVID-19 Treatment ????Microorganisms http://www.kidney.de/pget.php?&tw=1&pmid=32707942 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32707942 #FOAvip English Wikipedia <ref>{{Cite pmid|32707942}}</ref> Evaluation of Current Therapies for COVID-19 Treatment #MMPMID32707942 Sethi A; Bach H Microorganisms 2020[Jul]; 8 (8): ä PMID32707942show ga The virus SARS-CoV-2, the etiological agent of COVID-19, is responsible for more than 400,000 deaths worldwide as of 10 June 2020. As a result of its recent appearance (December 2019), an efficacious treatment is not yet available. Although considered a lung infection since its emergence, COVID-19 is now causing multiple organ failure, requiring a continuous adjustment in the procedures. In this review, we summarize the current literature surrounding unproven therapies for COVID-19. Analyses of the clinical trials were grouped as chemotherapy, serotherapy, anticoagulant, and the use of human recombinant soluble ACE2 therapies. We conclude that, while no agent has hit the threshold for quality of evidence to demonstrate efficacy and safety, preliminary data show potential benefits. Moreover, there is a possibility for harm with these unproven therapies, and the decision to treat should be based on a comprehensive risk-benefit analysis. äEvaluation of Current Therapies for COVID-19 Treatment (epmc).pdf DeepDyve Pubget Overpricing